Ever treated with TNF-I* | Never-treated with TNF-I | |
---|---|---|
No of arthritis patients | ||
All combined | 5345 | 4351 |
RA | 3347 | 3812 |
Ankylosing spondylitis | 861 | 136 |
Psoriatic arthritis | 656 | 224 |
Other arthritides | 481 | 179 |
Characteristics of RA patients at start of follow-up | ||
Mean age at start of follow-up, years (range) | 54.3 (15–87) | 61.2 (15–92) |
Mean age at diagnosis, years | 44.9 | 51.8 |
No of men (%) | 902 (27) | 998 (26) |
Calendar year of inclusion | ||
2000–1 | 379 | 92 |
2002–3 | 561 | 46 |
2004–5 | 948 | 62 |
2006–7 | 1069 | 2807 |
2008 | 390 | 805 |
No of IgM RF seropositive† (%) | 2411 (80) | 2593 (74) |
Mean disease duration, years (range) | 10.7 (0–59) | 8.9 (0–68) |
Proportion with disease duration <2 years | 18.7% | 31.6% |
Mean no of tender joints of 28 count† (range) | 9.6 (0–28) | 4.1 (0–28) |
Mean no of swollen joints of 28 count† (range) | 7.4 (0–28) | 2.8 (0–28) |
Mean HAQ score† (range) | 1.3 (0–9.6) | 0.7 (0–3.0) |
Mean CRP, mg/l† (range) | 27.0 (0–363) | 15.2 (0–232) |
Mean DAS28† (range) | 5.1 (1.2–8.5) | 3.5 (1.0–8.4) |
*The number of rheumatoid arthriris (RA) patients ever treated with adalimumab was 1529 (46%), etanercept 1488 (44%) and infliximab 1617 (48%).
†Patients with missing values were not included. The percentage of patients with missing values was as follows (ever tumour necrosis factor α inhibitor (TNF-I) treated, never-treated): number of IgM rheumatoid factor (RF) seropositive (9.7%, 8.4%), number of tender joints (7.3%, 3.5%), number of swollen joints (5.7%, 3.3%), health assessment questionnaire (HAQ) score (18.1%, 16.6%), C-reactive protein (CRP) (6.4%, 12.3%), disease activity score in 28 joints (DAS28) (20.4%, 29.4%).